Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $32.30 in the prior trading day, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $32.55, up 0.77%. In other words, the price has increased by $0.77 from its previous closing price. On the day, 1.08 million shares were traded.
Ratios:
Our goal is to gain a better understanding of CRNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.38 and its Current Ratio is at 16.38. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Jefferies Upgraded its Hold to Buy on January 22, 2025, while the target price for the stock was maintained at $55.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 03 ’25 when Pizzuti Dana sold 5,000 shares for $39.07 per share. The transaction valued at 195,350 led to the insider holds 31,748 shares of the business.
DANA J PIZZUTI bought 5,000 shares of CRNX for $195,372 on Feb 03 ’25. On Jan 03 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 15,000 shares for $52.09 each. As a result, the insider received 781,350 and left with 29,248 shares of the company.
Stock Price History:
Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $31.84. The 50-Day Moving Average of the stock is -23.99%, while the 200-Day Moving Average is calculated to be -34.69%.
Shares Statistics:
A total of 92.74M shares are outstanding, with a floating share count of 86.57M. Insiders hold about 6.65% of the company’s shares, while institutions hold 104.00% stake in the company.
